Circulating microRNA-based screening tool for breast cancer.
Circulating microRNA-based screening tool for breast cancer.
复制标题
DOI：
10.18632/oncotarget.6786
复制
发表时间：
2016-02-02
期刊：
影响因子：
--
通讯作者：
Jerusalem G
中科院分区：
文献类型：
--
作者：
Frères P;Wenric S;Boukerroucha M;Fasquelle C;Thiry J;Bovy N;Struman I;Geurts P;Collignon J;Schroeder H;Kridelka F;Lifrange E;Jossa V;Bours V;Josse C;Jerusalem G
循环microRNA（miRNAs）越来越被认为是包括乳腺癌在内的多种病理学中的有力生物标志物。在这里，测量它们的血浆水平以用作乳腺癌诊断的乳房X线摄影的替代筛查程序。在378名女性的队列中通过RT-qPCR确定血浆miRNA谱。基于首先在由41个原发性乳腺癌和45个对照组成的谱分析队列中测量的8种miRNA的表达设计诊断模型，并在由108个原发性乳腺癌、88个对照、35个缓解期乳腺癌、31个转移性乳腺癌和30个妇科肿瘤组成的不同队列中进一步验证。从基于8-miRNA随机森林的诊断工具得到的受试者操作特征曲线显示出0.81的曲线下面积。考虑到年龄和肿瘤分期，诊断工具的准确性保持不变。miRNA标签正确识别了转移性乳腺癌患者。对缓解期乳腺癌和妇科癌症患者队列使用分类模型，得到了与对照组相似的预测分布。使用多变量监督学习方法和一组8种循环miRNA，我们设计了一种准确的乳腺癌微创筛查工具。
Circulating microRNAs (miRNAs) are increasingly recognized as powerful biomarkers in several pathologies, including breast cancer. Here, their plasmatic levels were measured to be used as an alternative screening procedure to mammography for breast cancer diagnosis. A plasma miRNA profile was determined by RT-qPCR in a cohort of 378 women. A diagnostic model was designed based on the expression of 8 miRNAs measured first in a profiling cohort composed of 41 primary breast cancers and 45 controls, and further validated in diverse cohorts composed of 108 primary breast cancers, 88 controls, 35 breast cancers in remission, 31 metastatic breast cancers and 30 gynecologic tumors. A receiver operating characteristic curve derived from the 8-miRNA random forest based diagnostic tool exhibited an area under the curve of 0.81. The accuracy of the diagnostic tool remained unchanged considering age and tumor stage. The miRNA signature correctly identified patients with metastatic breast cancer. The use of the classification model on cohorts of patients with breast cancers in remission and with gynecologic cancers yielded prediction distributions similar to that of the control group. Using a multivariate supervised learning method and a set of 8 circulating miRNAs, we designed an accurate, minimally invasive screening tool for breast cancer.